AngioDynamics, Inc. (NASDAQ:ANGO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On January 10, 2017, James C. Clemmer, President and Chief
Executive Officer of AngioDynamics, Inc. (AngioDynamics
or the Company), and Michael C. Greiner, Executive Vice
President and Chief Financial Officer of the Company, will
present to certain investors at the JP Morgan 35th Annual
Healthcare Conference. The conference slides are furnished
herewith as Exhibit 99.1.
The slides are being furnished to Item 7.01 and the information
contained therein shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities under that Section.
Furthermore, the information in Exhibit 99.1 shall not be
deemed to be incorporated by reference into the filings of the
Company under the Securities Act of 1933, as amended.
Forward-Looking Statements
This document and its attachments contain forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements regarding
AngioDynamics expected future financial position, results of
operations, cash flows, business strategy, budgets, projected
costs, capital expenditures, products, competitive positions,
growth opportunities, plans and objectives of management for
future operations, as well as statements that include the words
such as expects, reaffirms, intends, anticipates, plans,
believes, seeks, estimates, optimistic, or variations of such
words and similar expressions, are forward-looking statements.
These forward looking statements are not guarantees of future
performance and are subject to risks and uncertainties. Investors
are cautioned that actual events or results may differ from
AngioDynamics expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation,
the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by
competitors, infringement of AngioDynamics technology or
assertions that AngioDynamics technology infringes the technology
of third parties, the ability of AngioDynamics to effectively
compete against competitors that have substantially greater
resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials,
overall economic conditions, the results of on-going litigation,
challenges with respect to third-party distributors or joint
venture partners or collaborators, the results of sales efforts,
the effects of product recalls and product liability claims,
changes in key personnel, the ability of AngioDynamics to execute
on strategic initiatives, the effects of economic, credit and
capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the
effects on pricing from group purchasing organizations and
competition, the ability of AngioDynamics to integrate purchased
businesses, as well as the risk factors listed from time to time
in AngioDynamics SEC filings, including but not limited to its
Annual Report on Form 10-K for the year ended May 31, 2016 and
its quarterly reports on Form 10-Q for the fiscal periods ended
August 31, 2016 and November 30, 2016. AngioDynamics does not
assume any obligation to publicly update or revise any
forward-looking statements for any reason.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1 |
Presentation slides for the JP Morgan Healthcare Conference on January 10, 2017 |
About AngioDynamics, Inc. (NASDAQ:ANGO)
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines. AngioDynamics, Inc. (NASDAQ:ANGO) Recent Trading Information
AngioDynamics, Inc. (NASDAQ:ANGO) closed its last trading session up +0.45 at 17.45 with 467,934 shares trading hands.
